12/21
Headlines

Mark DeFrance

Mark DeFrance is a senior research analyst at Tech Insider, focusing on the enterprise software sector. Prior to joining TI, Mark covered enterprise software for First Albany, and prior to that he worked in equity research at B.T. Alex Brown and Bankers Trust. Mark has written software applications in various programming languages including BASIC, Pascal, and COBOL. He has also been recognized in The Wall Street Journal's "Best on the Street" survey and was recognized by Forbes Magazine as the No. 1 sell-side stock picker in the software industry for a five-year period, with returns of 115% versus 26% for the software industry.

Stocks Moving After-Hours: Regeneron Pharmaceuticals Inc (NASDAQ:REGN), Kinder Morgan Management (NYSE:KMR), FutureFuel (NYSE:FF)

Mark DeFrance02 mins

Citigroup upgraded it rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company’s Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron’s pipeline is not adequately reflected in the current share price. The firm raised its price target for the…

Read More
FB Nasdaq FB Facebook

Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Mark DeFrance02 mins

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a…

Read More

Most Active Solar Stocks: JA Solar (NASDAQ:JASO), Yingli Green Energy (NYSE:YGE), First Solar (NASDAQ:FSLR), Solar City (NASDAQ:SCTY)

Mark DeFrance03 mins

JA Solar Holdings (NASDAQ:JASO) reached a more than two-year high Monday after reporting Q4 results that beat analyst estimates. The Chinese maker of solar cells reported non-GAAP earnings of RMB 0.94, or $0.16, per diluted ADS, compared with the Capital IQ estimate for a loss of $0.06 a share. Q4 net revenue grew 30% from…

Read More

Biotech active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG), Ariad Pharmaceuticals (NASDAQ:ARIA)

Mark DeFrance02 mins

Bristol-Myers Squibb & Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced today that the FDA has approved an additional indication of Bristol’s anti-blood clot medicine, Eliquis. Pfizer Inc. (NYSE:PFE) stock performance was 0.35% in last session and finished the day at $31.23. Traded volume was 27.11 million shares in the last session and the average volume…

Read More

Biotech Stocks Touching New Highs: Relypsa Inc. (NASDAQ:RLYP), Vanda Pharmaceuticals (NASDAQ:VNDA), OHR Pharmaceutical (NASDAQ:OHRP), Xencor (NASDAQ:XNCR)

Mark DeFrance02 mins

Relypsa, Inc. (NASDAQ:RLYP) is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa Inc. (NASDAQ:RLYP) stock performance was 2.66% in last session and finished the day at $43.62. Traded volume was 126,739.00 shares in the last session and…

Read More

Money Center Banks: Bank of America Corp (NYSE:BAC), Citigroup Inc (NYSE:C), JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Co (NYSE:WFC)

Mark DeFrance02 mins

Bank of America Corp (NYSE:BAC) Merrill Lynch analysts also lowered their prediction from 7.6 per cent to 7.2 per cent for the full year due to the “significantly weaker than expected” data in the first two months. Bank of America Corp (NYSE:BAC) stock performance was -2.10% in last session and finished the day at $16.80….

Read More